SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
2 people’s side silhouettes overlaid with various sized semi-transparent vaccine syringes and virus particles shapes. A large translucent question mark represents key questions and concerned thoughts.
Opinion
A Flu Season in Flux Presents Risks, Opportunities for Biopharma
The coming flu season is the clearest indication yet that biopharma’s long-standing assumptions about predictability, prevention and portfolio structure are no longer guaranteed.
October 28, 2025
 · 
7 min read
 · 
Tom Sebok
Success roadmap journey, milestone or career path achievement, route or pathway to achieve goals, accomplishment, assessment or way to success, businessman look at achievement milestone to success.
Manufacturing
Pharmas Hope FDA PreCheck Can Help Avoid Facility-Related Drug Rejections
Executives from Eli Lilly, Merck and other companies foresee the FDA’s new onshoring proposal being anything from a bureaucratic waste of time to a transformative program that will eliminate inspection-related complete response letters.
October 28, 2025
 · 
4 min read
 · 
Nick Paul Taylor
Creative picture image collage banner of guy worker jump from financial charts determined company success.
Neuroscience
BridgeBio Pops on Late-Stage Limb-Girdle Muscular Dystrophy Data
New interim data from a Phase III trial puts the company on track to file for FDA approval next year in an indication that not only lacks a disease-modifying treatment but suffered significant setbacks after a patient died in a clinical trial for Sarepta’s investigational gene therapy.
October 27, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Special edition
Deep Dive: Chinese Biotech Innovation Can’t Be Stopped
In this deep dive, BioSpace investigates China’s rise as a biotech powerhouse.
October 27, 2025
 · 
3 min read
 · 
Annalee Armstrong
Red round circle with a pause button or icon against yellow background.
Rare diseases
Intellia Pauses Phase III ATTR Trials for CRISPR Gene Therapy After Life-Threatening Liver Toxicity
Intellia earlier this year reported a similar grade 4 liver enzyme elevation associated with the gene therapy nexiguran ziclumeran, though analysts at BMO Capital Markets at the time brushed it off as a “non-concern.”
October 27, 2025
 · 
2 min read
 · 
Tristan Manalac
3D illustration of many pawns attracted by a red one. Concept of aura of attraction and charismatic person.3D rendering on black background.
Rare diseases
Dyne Primed for Suitors Amid Novartis’ $12B Avidity Acquisition
The takeover of its competitor, announced Sunday, could also bring some attention to Dyne Therapeutics, which has a similar RNA-based pipeline in rare muscle diseases.
October 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Bayer's factory and office in Berlin
Approvals
Bayer Gets FDA Nod for Novel Drug to Treat Hot Flashes
Lynkuet is the first FDA-approved therapy that blocks both the neurokinin 1 and neurokinin 3 receptors to treat hot flashes.
October 27, 2025
 · 
1 min read
 · 
Tristan Manalac
Sponsored
Best Pharmaceutical Label Manufacturers: Reviews and Comparisons
Selecting the ideal pharmaceutical label manufacturer requires careful consideration. This article compares leading companies, highlighting their strengths in regulatory compliance, material performance, serialization, innovation, and sustainability, to help you make an informed decision for your product’s safety and success.
October 27, 2025
 · 
6 min read
Daniel and Kaori Barvin sharing their story of lay leadership at the Seattle Jewish Federation's Fall Fundraiser.
ALS
Coya Exec Daniel Barvin Is on a Mission To End Genetic ALS and FTD
The BioSpace 40 Under 40 winner opens up about his very personal career transformation from wealth management to biotech—and what it’s like to develop a drug for amyotrophic lateral sclerosis and frontotemporal dementia as a potential patient himself.
October 27, 2025
 · 
5 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS